This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.


Addressing respiratory conditions is a priority identified in the NHS Long Term Plan (2019). The Oxford AHSN supports the national focus on increasing detection and diagnosis, and reducing mortality, morbidity and inequalities.

We lead the national collective AHSN programme to increase uptake of biologic medicines to improve outcomes for patients with severe and uncontrolled asthma. Asthma biologics can transform patient lives by reducing asthma attacks, asthma-related hospital admissions and long-term side-effects of other treatments such as oral steroids.

We support Wessex AHSN which is the national lead for the programme to increase use of FeNO (fractional exhaled nitric oxide) testing in asthma diagnosis and management.

Our patient safety team works with NHS organisations in our region to implement a national patient safety improvement programme to support the spread of effective, evidence-based practice through increased uptake of discharge care bundles for asthma and chronic obstructive pulmonary disease. Read more here.

Locally we are also working to strengthen networks, with a particular focus on improving links between primary and secondary care, and supporting workforce innovation.

In addition, we work with innovators to support the translation of research and development into clinical practice and provide effective signposting and advice to companies seeking to develop and evaluate new diagnostic, digital, medical device and artificial intelligence technologies. A number of these are related to respiratory conditions.

Respiratory is one of four key health and care priorities for the Oxford AHSN in 2022/23. Read more about them here or click on the image below.